{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/anticoagulation-oral/management/apixaban/","result":{"pageContext":{"chapter":{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban","depth":2,"htmlHeader":"<!-- begin field addeccbc-721a-439c-a0d8-ec758f79422d --><h2>Scenario: Apixaban</h2><!-- end field addeccbc-721a-439c-a0d8-ec758f79422d -->","summary":"Covers prescribing and management information for adults receiving apixaban for use within its licensed indication.","htmlStringContent":"<!-- begin item 8987b19b-1e19-4905-9c29-b8d74846eea5 --><!-- begin field 95a62803-6504-4cbb-b671-acd900add828 --><p>From age 16 years onwards.</p><!-- end field 95a62803-6504-4cbb-b671-acd900add828 --><!-- end item 8987b19b-1e19-4905-9c29-b8d74846eea5 -->","topic":{"id":"5e046307-14e1-50a6-9729-69af5ae00b78","topicId":"d64523b7-19f2-41a0-afd4-d1c0790cce30","topicName":"Anticoagulation - oral ","slug":"anticoagulation-oral","lastRevised":"January 2021","chapters":[{"id":"b5dcda3e-cc4c-56b5-9348-00f8e8eb8e32","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2424a367-7b32-59ea-8783-9d80a1a68c3c","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"02a83663-a0e4-533a-a0a3-a6b15235867c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"31157a72-4e11-5ad4-8139-919ce4241f22","slug":"changes","fullItemName":"Changes"},{"id":"14f1139a-434d-530b-be52-9692e9271a76","slug":"update","fullItemName":"Update"}]},{"id":"67dfc47b-2285-596f-9f26-279a85f25dcc","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4b943e8-803b-51b4-a154-3a58c4bbaf1a","slug":"goals","fullItemName":"Goals"},{"id":"1a8fff43-5d5a-5e06-803b-ea61542c56a4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a1c4ef1a-272a-56c2-bba9-b437e8b0e03d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"54bcfbdc-7506-5ca1-ae0c-e5ab55acb001","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2387aba8-f14a-5fc6-8335-485e08a6c959","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"dd9aca34-523a-570a-bb3f-422e7bf450a7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"772f3b00-3aa4-5b51-aad4-43ff44e987d3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e9b14f86-2066-57e8-9b9f-65926e978b59","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"55f43edd-e0fd-5e66-a53b-36ef8f137cd3","slug":"licensed-indications","fullItemName":"Licensed indications"}]},{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","fullItemName":"Management","slug":"management","subChapters":[{"id":"46bb380b-6d51-5ede-b5dc-78ec7987f404","slug":"apixaban","fullItemName":"Scenario: Apixaban"},{"id":"e4a2d921-e87f-5760-a17a-271fefa9d1c4","slug":"dabigatran","fullItemName":"Scenario: Dabigatran"},{"id":"e0aace92-5b9a-53c2-af09-6318f0911654","slug":"edoxaban","fullItemName":"Scenario: Edoxaban"},{"id":"015cbcc5-4efe-568f-9643-d7a22d37b286","slug":"rivaroxaban","fullItemName":"Scenario: Rivaroxaban"},{"id":"693e35a4-4b44-514c-847c-855a53793f98","slug":"warfarin","fullItemName":"Scenario: Warfarin"}]},{"id":"3d346e04-bfd5-53aa-9cbe-bee5c6a912bb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"76dbe1dd-0d3b-50e8-9472-5af55550c77a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"5f762de3-78b6-55d7-b9bb-cc3f1cb77bea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0c725a38-4d35-5fbd-bd5d-b48afc70e783","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2b9eb7d5-9bc8-5af8-b91f-75e9b1480d83","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"33630559-9216-56bf-9890-6bbe997245bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51bd3b51-3e20-5f51-a925-74b2c904fd53","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"54dbb8de-8bee-5c53-b63b-9645b55e6b5d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1432aebe-6008-53bc-915b-8f136a3cc1e6","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"a8bd8d8f-58dd-5fbc-b2df-95bb30944867","slug":"recommended-dose-treatment-duration","fullItemName":"Recommended dose and treatment duration","depth":3,"htmlHeader":"<!-- begin field b3fd116f-115f-417b-9a68-c6d167c8bf06 --><h3>What is the recommended dose and duration of treatment for apixaban?</h3><!-- end field b3fd116f-115f-417b-9a68-c6d167c8bf06 -->","summary":null,"htmlStringContent":"<!-- begin item 44090d15-90f0-4bcd-82c0-00bfa8c0c92d --><!-- begin field 5a71f0b1-ffc1-4b11-9320-cd22510d7d23 --><ul><li><strong>For the prophylaxis of stroke and systemic embolism in adults with non-valvular atrial fibrillation and at least one risk factor, such as previous stroke or transient ischaemic attack, symptomatic heart failure, diabetes mellitus, hypertension, or age 75 years and over:</strong><ul><li>The recommended dose is 5 mg twice a day.</li><li>The dose should be reduced to 2.5 mg twice daily if the person has at least two of the following characteristics:<ul><li>Age 80 years or older. </li><li>Body weight 60 kg or less. </li><li>Creatinine clearance (CrCl) 15–30 mL/minute, or serum creatinine 1.5 mg/dL (133 micromol/L) or more.</li></ul></li><li>Treatment is usually long term.</li></ul></li><li><strong>For the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE):</strong><ul><li>The recommended dose is 10 mg twice daily for the first 7 days, followed by 5 mg twice daily.</li><li>The duration of treatment should be based on the presence of transient risk factors (for example, recent surgery, trauma, and immobilization), but it should be for a minimum of 3 months.</li></ul></li><li><strong>For the <strong>prophylaxis</strong> of recurrent DVT and PE in adults </strong>(following completion of 6 months of anticoagulation treatment):<ul><li>The recommended dose is 2.5 mg twice daily.</li><li>The duration of treatment is based on an assessment of benefit against the risk of bleeding.</li></ul></li><li><strong>For the <strong>prophylaxis</strong> of venous thromboembolism (VTE) i</strong><strong>n people who have undergone hip replacement surgery:</strong><ul><li>The recommended dose is 2.5 mg twice daily for 32–38 days, to be started 12–24 hours after surgery.</li></ul></li><li><strong>For the prophylaxis of VTE in people who have undergone knee replacement surgery: </strong><ul><li>The recommended dose is 2.5 mg twice daily for 10–14 days, to be started 12–24 hours after surgery.</li></ul></li></ul><!-- end field 5a71f0b1-ffc1-4b11-9320-cd22510d7d23 --><!-- end item 44090d15-90f0-4bcd-82c0-00bfa8c0c92d -->","subChapters":[{"id":"1ba9c8b3-5af3-5488-8683-a6b1166a3fd0","slug":"basis-for-recommendation-f33","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 97069dfd-dd4d-4c9c-9656-04d973e6a795 --><h4>Basis for recommendation</h4><!-- end field 97069dfd-dd4d-4c9c-9656-04d973e6a795 -->","summary":null,"htmlStringContent":"<!-- begin item f33af677-d92b-4aa3-8ebb-eee56335f643 --><!-- begin field 2f65604e-8caf-4c6a-9d2a-2b2cfefe7d32 --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 2f65604e-8caf-4c6a-9d2a-2b2cfefe7d32 --><!-- end item f33af677-d92b-4aa3-8ebb-eee56335f643 -->","subChapters":[]}]},{"id":"0da48a7e-af5f-5db8-9a54-c2c1129b61ac","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 46be33ca-426c-4063-ad11-2aa98df142a7 --><h3>What are the contraindications and cautions for apixaban?</h3><!-- end field 46be33ca-426c-4063-ad11-2aa98df142a7 -->","summary":null,"htmlStringContent":"<!-- begin item 3c225491-51d6-4e0c-9e3b-7cc389e16e32 --><!-- begin field 416f958b-42d1-484a-a4f9-e5eefe6c355c --><ul><li><strong>Apixaban is contraindicated in:</strong><ul><li>People with:<ul><li>Creatinine clearance (CrCl) less than 15 mL/minute.</li><li>Liver disease associated with coagulopathy and clinically relevant bleeding risk.</li><li>A prosthetic heart valve — efficacy not established.</li><li>Antiphospholipid syndrome — increased risk of recurrent thrombotic events.</li><li>Active bleeding.</li></ul></li><li>People with a significant risk of major bleeding, such as:<ul><li>Current or recent gastrointestinal ulcer.</li><li>Oesophageal varices.</li><li>Recent brain or spinal injury.</li><li>Recent brain, spine, or ophthalmic surgery.</li><li>Recent intracranial haemorrhage.</li><li>Malignant neoplasm at high risk of bleeding.</li><li>Vascular aneurysm.</li><li>Arteriovenous malformations.</li><li>Major intraspinal or intracerebral vascular abnormalities.</li></ul></li><li>Women who are pregnant or breastfeeding — the safety of apixaban has not been established in these groups.</li></ul></li><li><strong>Apixaban should be prescribed with caution in the following groups:</strong><ul><li>Elderly people (age 80 years or older) — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated.</li><li>People with:<ul><li>Body weight of 60 kg or less — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated (low body weight may increase plasma concentrations of apixaban).</li><li>Moderate renal impairment (CrCl 15–30 mL/minute) — <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#recommended-dose-treatment-duration\">dose reduction</a> is indicated (approximately 27% of apixaban is excreted renally).</li></ul></li><li>People on concurrent treatment with other drugs that can cause bleeding, such as nonsteroidal anti-inflammatory drugs (NSAIDs) — if concurrent treatment is unavoidable, close monitoring for signs of bleeding and anaemia is recommended. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#drug-interactions\">Drug interactions</a> for more information, and for information on other drug interactions of apixaban.</li></ul></li></ul><!-- end field 416f958b-42d1-484a-a4f9-e5eefe6c355c --><!-- end item 3c225491-51d6-4e0c-9e3b-7cc389e16e32 -->","subChapters":[{"id":"03027dbb-fed0-5e98-b21d-472c60d943a6","slug":"basis-for-recommendation-07d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 049bb9c6-13d6-45f1-a9fc-4c89028f70eb --><h4>Basis for recommendation</h4><!-- end field 049bb9c6-13d6-45f1-a9fc-4c89028f70eb -->","summary":null,"htmlStringContent":"<!-- begin item 07d40472-7cc9-4e3d-9abf-99d2de2c1e30 --><!-- begin field de1d79e0-e49e-4ae7-b993-f9694159d33d --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>], the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>], and Drug Safety Updates issued by the Medicines and Healthcare products Regulatory Agency (MHRA): <em>Direct-acting oral anticoagulants (DOACs): increased risk of recurrent thrombotic events in patients with antiphospholipid syndrome</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2019a</a>] and <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</p><h5>Prosthetic heart valves</h5><ul><li>The manufacturer states that the safety and efficacy of apixaban have not been studied in people with prosthetic heart valves, with or without atrial fibrillation. Therefore, the use of apixaban is not recommended in this group of people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>].</li></ul><h5>Antiphospholipid syndrome</h5><ul><li>A clinical trial has shown an increased risk of recurrent thrombotic events associated with rivaroxaban compared with warfarin in people with antiphospholipid syndrome and a history of thrombosis; there may be a similar risk associated with other DOACs. The MHRA advises that DOACs are not recommended in people with antiphospholipid syndrome, particularly high-risk individuals who test positive for all three antiphospholipid tests — lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Continued treatment should be reviewed in these people to determine if appropriate and switching to a vitamin K antagonist (such as warfarin) should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2019a</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with apixaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are also advised to use apixaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li></ul><h5>Renal function</h5><ul><li>Expert opinion in the European Heart Rhythm Association (EHRA) guideline is that approximately 27% of apixaban is excreted renally. Exposure to apixaban is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</li></ul><!-- end field de1d79e0-e49e-4ae7-b993-f9694159d33d --><!-- end item 07d40472-7cc9-4e3d-9abf-99d2de2c1e30 -->","subChapters":[]}]},{"id":"47d4aa02-2e23-5663-bb12-e9ab27d8d29e","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field c3f4563d-58eb-4a37-a4bd-ed158b76a5ab --><h3>What are the adverse effects of apixaban?</h3><!-- end field c3f4563d-58eb-4a37-a4bd-ed158b76a5ab -->","summary":null,"htmlStringContent":"<!-- begin item 83a1fb25-c68e-4652-b4fb-96c5e8b6db0a --><!-- begin field ec8968d3-a361-4961-ba3b-3df49a684e30 --><ul><li><strong>Bleeding is a common adverse effect of all anticoagulants, including apixaban, </strong><strong>and it can occur in any part of the body.</strong><ul><li>Advise people taking apixaban to:<ul><li style=\"box-sizing: inherit;\">Seek immediate medical advice if spontaneous bleeding occurs and does not stop, or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li style=\"box-sizing: inherit;\">Seek medical advice if they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li style=\"box-sizing: inherit;\">Get advice from a doctor or pharmacist before taking other medications, including over-the-counter medicines (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#drug-interactions\">drug interactions</a> with apixaban.</li></ul></li><li>Andexanet alfa (Ondexxya®) is a specific reversal agent indicated for adults treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.</li></ul></li><li><strong>Other adverse effects of apixaban include:</strong><ul><li>Common — anaemia, bruising, nausea, and skin reactions.</li><li>Uncommon — angioedema, hypotension, post procedural haematoma, thrombocytopenia, and wound complications.</li></ul></li></ul><!-- end field ec8968d3-a361-4961-ba3b-3df49a684e30 --><!-- end item 83a1fb25-c68e-4652-b4fb-96c5e8b6db0a -->","subChapters":[{"id":"6f8a1b78-92b6-5047-9a7b-bae326199a6c","slug":"basis-for-recommendation-335","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ae29ab44-3232-4506-9db7-93a9f3fc34d8 --><h4>Basis for recommendation</h4><!-- end field ae29ab44-3232-4506-9db7-93a9f3fc34d8 -->","summary":null,"htmlStringContent":"<!-- begin item 335d7393-9cfe-4475-b7fe-4432f4fa0fac --><!-- begin field c898769c-4d41-4abf-9693-e97833afe37f --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>], the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>], and the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>]. </p><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with apixaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are advised to use apixaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. The person should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li><li>Andexanet alfa (Ondexxya®) is a reversal agent for apixaban (and rivaroxaban) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>]. It is a recombinant form of human factor Xa protein which binds specifically to apixaban (and rivaroxaban), thereby reversing their anticoagulant effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field c898769c-4d41-4abf-9693-e97833afe37f --><!-- end item 335d7393-9cfe-4475-b7fe-4432f4fa0fac -->","subChapters":[]}]},{"id":"8b3590b5-9677-5f94-b6a3-ed9c3fe8e034","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field cd7ba7b1-bb9b-484f-97df-d05e946fd575 --><h3>What are the key drug interactions for apixaban?</h3><!-- end field cd7ba7b1-bb9b-484f-97df-d05e946fd575 -->","summary":null,"htmlStringContent":"<!-- begin item 819dfc11-3920-457b-9f53-d5a29c28d829 --><!-- begin field 0b0b07aa-b1b1-4baa-865a-85795ef54992 --><ul><li><strong>Key drug interactions with apixaban include:</strong><ul><li><strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) </strong>— apixaban is predicted to increase the risk of bleeding events when given with NSAIDs (such as ibuprofen). <ul><li>The manufacturer of apixaban advises to avoid.</li><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li><li><strong>Other anticoagulants, such as heparin, warfarin, rivaroxaban, or dabigatran </strong>— there is an increased risk of bleeding if other anticoagulants are given with apixaban. <ul><li>Avoid concurrent use except when switching to or from warfarin treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/#switching-anticoagulants\">Switching anticoagulants</a> for more information.</li></ul></li><li><strong>Antiplatelets, such as aspirin, clopidogrel, and ticagrelor </strong>— apixaban is predicted to increase the risk of bleeding events when given with antiplatelet drugs. <ul><li>The manufacturer of apixaban advises to avoid.</li><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li><li><strong>Strong inhibitors of both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), such as </strong><strong>itraconazole, ketoconazole, and HIV protease inhibitors (for example ritonavir) </strong>— plasma concentration of apixaban is increased by these drugs.<ul><li>The manufacturer of apixaban advises to avoid concurrent use with these drugs.</li><li>For drugs that are not considered strong inhibitors of <em>both</em> CYP3A4 and P-gp, such as amiodarone, clarithromycin, diltiazem, fluconazole, quinidine, and verapamil, the plasma concentration of apixaban is increased to a lesser extent. No dose adjustment for apixaban is required with these drugs, but the person should be monitored for signs of bleeding or anaemia.</li></ul></li><li><strong>Strong inducers of both CYP3A4 and P-gp, such as carbamazepine, phenytoin, rifampicin, and St John's Wort </strong>— plasma concentration of apixaban may be reduced by these drugs.<ul><li>For the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and for the prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE), the person should be closely monitored for signs of thrombosis.</li><li>For the treatment of DVT and PE, apixaban should not be used since efficacy may be compromised.</li></ul></li><li><strong>Selective serotonin reuptake inhibitors (such as citalopram), serotonin norepinephrine re-uptake inhibitors (duloxetine), and venlafaxine </strong>— there is a possible increased risk of bleeding when apixaban is given with these antidepressants.<br><ul><li>The manufacturer of apixaban advises to avoid.</li><li>If concurrent use is indicated, monitor for signs of bleeding and anaemia.</li></ul></li></ul></li><li>See the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"bf6bda62-14be-48b6-a3bd-a98d000d45b6\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"f811dbb2-4c9a-4436-be05-a98d000d462f\">British National Formulary</a> (BNF) for other possible drug interactions with apixaban.</li></ul><!-- end field 0b0b07aa-b1b1-4baa-865a-85795ef54992 --><!-- end item 819dfc11-3920-457b-9f53-d5a29c28d829 -->","subChapters":[{"id":"5d96ce40-4552-50d6-a35c-af7ac21a9b8c","slug":"basis-for-recommendation-353","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fea0666b-a6be-4e5f-aecc-45576338343b --><h4>Basis for recommendation</h4><!-- end field fea0666b-a6be-4e5f-aecc-45576338343b -->","summary":null,"htmlStringContent":"<!-- begin item 3535e2aa-113e-4d51-b7d3-8ddf15aa20ac --><!-- begin field 9d96a28a-2d60-4af7-93a6-ee6f29466901 --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>] and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><!-- end field 9d96a28a-2d60-4af7-93a6-ee6f29466901 --><!-- end item 3535e2aa-113e-4d51-b7d3-8ddf15aa20ac -->","subChapters":[]}]},{"id":"861af7af-4c4f-5ea3-bc8d-1a05177247b8","slug":"switching-anticoagulants","fullItemName":"Switching anticoagulants","depth":3,"htmlHeader":"<!-- begin field 1e256c08-9f96-4227-b332-483e82b1e819 --><h3>How should I switch a person to or from another anticoagulant?</h3><!-- end field 1e256c08-9f96-4227-b332-483e82b1e819 -->","summary":null,"htmlStringContent":"<!-- begin item 1c21022b-bf06-4947-ab89-8566324a1a9d --><!-- begin field 9b65b027-f97b-4991-a36f-d4828ba2246a --><ul><li><strong>Switching from warfarin to apixaban:</strong><ul><li>Stop warfarin, and measure the international normalized ratio (INR):<ul><li>If the INR is less than 2, start apixaban.</li><li>If the INR is between 2 and 2.5, start apixaban the next day.</li><li>If the INR is greater than 2.5, wait until the person's INR has dropped to less than 2 before starting apixaban.</li></ul></li><li>The time taken for the person's INR to reach less than 2 will vary from person to person and will depend on what the person's initial INR level was.</li></ul></li><li><strong>Switching from apixaban to warfarin:</strong><ul><li>Start warfarin, but <em>do not </em>stop apixaban. <ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/warfarin/#starting-warfarin-treatment\">Starting warfarin treatment</a> for information on how to initiate warfarin treatment.</li></ul></li><li>After at least 2 days of concurrent treatment with warfarin and apixaban, measure the INR prior to the next scheduled dose of apixaban.<ul><li>If the INR is in the target range, stop apixaban and continue with warfarin.</li><li>If the INR is not in the target range, continue warfarin and apixaban concurrently until the person's INR is in the target range, then stop apixaban. Warfarin has a slow onset of action and it may take 5–10 days before the INR is within range. </li></ul></li><li>After treatment with apixaban has stopped:<ul><li>Measure the INR after 24 hours to ensure adequate anticoagulation.</li><li>Monitor the person's INR closely (for example once a week) in the first month of warfarin treatment until the person has three consecutive stable INR values (for example between 2–3).</li></ul></li></ul></li><li><strong>Switching from apixaban to another direct-acting oral anticoagulant (DOAC):</strong><ul><li>Stop apixaban, and start the new DOAC (dabigatran, edoxaban, or rivaroxaban) when the next dose of apixaban is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval in between DOACs is recommended.</li></ul></li></ul></li><li><strong>Switching from another DOAC to apixaban:</strong><ul><li>Stop the initial DOAC (dabigatran, edoxaban, or rivaroxaban), and start apixaban when the next dose of the initial DOAC (dabigatran, edoxaban, or rivaroxaban) is due.<ul><li>In situations where higher than therapeutic plasma concentrations are expected, such as in people with impaired renal function, a longer interval between DOACs is recommended.</li></ul></li></ul></li></ul><!-- end field 9b65b027-f97b-4991-a36f-d4828ba2246a --><!-- end item 1c21022b-bf06-4947-ab89-8566324a1a9d -->","subChapters":[{"id":"81f848f6-52cf-56c9-82c2-56b44f0effdf","slug":"basis-for-recommendation-6e1","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4544ca1f-023f-4022-95a0-dc1a454c082e --><h4>Basis for recommendation</h4><!-- end field 4544ca1f-023f-4022-95a0-dc1a454c082e -->","summary":null,"htmlStringContent":"<!-- begin item 6e1736ee-26a5-43f1-947f-871d2fe5e1b1 --><!-- begin field f38053bb-2ec8-4c6e-b30b-fe32f16a1688 --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><!-- end field f38053bb-2ec8-4c6e-b30b-fe32f16a1688 --><!-- end item 6e1736ee-26a5-43f1-947f-871d2fe5e1b1 -->","subChapters":[]}]},{"id":"0fb73060-a07c-5346-9913-05f92f73fc36","slug":"surgery-dental-treatment","fullItemName":"Surgery and dental treatment","depth":3,"htmlHeader":"<!-- begin field 51e9840b-9b3a-463d-bbca-485853d9e150 --><h3>Should apixaban be stopped if surgery or dental treatment is required?</h3><!-- end field 51e9840b-9b3a-463d-bbca-485853d9e150 -->","summary":null,"htmlStringContent":"<!-- begin item d9d1b292-ac40-4b7e-9f82-7c178a9458c6 --><!-- begin field ed1c1266-d678-44ee-b1dd-06d95d0aadc9 --><ul><li><strong>If the person needs to have surgery or any other invasive procedure, they may need to temporarily stop taking apixaban.</strong> The decision to stop apixaban and when to stop it will depend on the person's risk of having a thromboembolic event and the bleeding risk associated with the procedure.</li><li><strong>For most minor surgical procedures and those associated with a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/#bleeding-risk\">minor bleeding risk</a>, </strong>it is recommended not to interrupt oral anticoagulation.<ul><li>In general, these procedures can be performed 12–24 hours after the last dose of apixaban is taken.</li><li>It may be practical to have the intervention scheduled 18–24 hours after the last dose of apixaban is taken, then restart apixaban 6 hours later. This means that one dose of apixaban may be missed.</li></ul></li><li><strong>For procedures with a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/#bleeding-risk\">low bleeding risk</a>, </strong>apixaban should be stopped at least 24 hours before the procedure.<ul><li>If creatinine clearance (CrCl) is 15–29 mL/minute, apixaban should be stopped at least 36 hours before the procedure.</li></ul></li><li><strong>For procedures with a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/dabigatran/#bleeding-risk\">high bleeding risk</a>,</strong> apixaban should be stopped at least 48 hours before the procedure.</li></ul><!-- end field ed1c1266-d678-44ee-b1dd-06d95d0aadc9 --><!-- end item d9d1b292-ac40-4b7e-9f82-7c178a9458c6 -->","subChapters":[{"id":"fff3bb6f-6819-53af-b8b3-42a1414cec5e","slug":"bleeding-risk","fullItemName":"Bleeding risk","depth":4,"htmlHeader":"<!-- begin field 7e6aa05f-a888-43e9-a32e-091477d4fbeb --><h4>Bleeding risk</h4><!-- end field 7e6aa05f-a888-43e9-a32e-091477d4fbeb -->","summary":null,"htmlStringContent":"<!-- begin item 7a221b9b-5307-4c93-a699-004302d26477 --><!-- begin field f6f75454-4e04-4633-be97-b8aef5f2a215 --><ul><li><strong>Treatments with minor bleeding risk include:</strong><ul><li>Dental interventions, such as extraction of 1 to 3 teeth, periodontal surgery, incision of abscess, and implant positioning.</li><li>Cataract or glaucoma interventions.</li><li>Endoscopy without surgery.</li><li>Minor surgery, such as abscess incision and small dermatologic excisions.</li></ul></li><li><strong>Treatments with low bleeding risk include:</strong><ul><li>Endoscopy with biopsy.</li><li>Prostate or bladder biopsy.</li><li>Electrophysiological study or radiofrequency catheter ablation for supraventricular tachycardia (including left-sided ablation via single trans-septal puncture).</li><li>Angiography.</li><li>Pacemaker or implantable cardioverter defibrillator (ICD) implantation (unless complex anatomical setting, for example congenital heart disease).</li></ul></li><li><strong>Treatments with high bleeding risk include:</strong><ul><li>Complex endoscopy, such as polypectomy and endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy.</li><li>Spinal or epidural anaesthesia.</li><li>Lumbar diagnostic puncture.</li><li>Thoracic surgery.</li><li>Abdominal surgery.</li><li>Major orthopaedic surgery.</li><li>Liver biopsy.</li><li>Transurethral prostate resection.</li><li>Kidney biopsy.</li><li>Extracorporeal shockwave lithotripsy (ESWL).</li></ul></li><li><strong>Treatments with high bleeding risk <em>and</em> increased thromboembolic risk include:</strong><ul><li>Complex left-sided ablation (pulmonary vein isolation, some VT ablations).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>]</p><!-- end field f6f75454-4e04-4633-be97-b8aef5f2a215 --><!-- end item 7a221b9b-5307-4c93-a699-004302d26477 -->","subChapters":[]},{"id":"6ae5ddc9-9eff-5e32-87a0-4a18a37e9658","slug":"basis-for-recommendation-6ec","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field fbedfd2f-0831-4456-b245-846e9ce47cf2 --><h4>Basis for recommendation</h4><!-- end field fbedfd2f-0831-4456-b245-846e9ce47cf2 -->","summary":null,"htmlStringContent":"<!-- begin item 6ecd571f-8c11-4779-bc0c-7ce3ae018796 --><!-- begin field 01c4f2c0-2a93-43e0-b1f1-c559859e5ed7 --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><h5>Minor bleeding risk</h5><ul><li>The European Heart Rhythm Association (EHRA) recommends not to interrupt oral anticoagulation for most minor surgical procedures and those procedures where bleeding is easily controllable. </li></ul><h5>Low bleeding risk</h5><ul><li>For invasive procedures with a low bleeding risk (that is, low frequency of bleeding and/or minor impact of bleeding), apixaban should be discontinued at least 24 hours before the procedure in most people, and at least 36 hours if creatinine clearance (CrCl) is 15–29 mL/minute.</li></ul><h5>High bleeding risk</h5><ul><li>For invasive procedures that carry a high risk for major bleeding (that is, with a high frequency of bleeding and/or important clinical impact), the EHRA recommends taking the last direct oral anticoagulant (DOAC) dose 48 hours or longer before surgery.</li></ul><!-- end field 01c4f2c0-2a93-43e0-b1f1-c559859e5ed7 --><!-- end item 6ecd571f-8c11-4779-bc0c-7ce3ae018796 -->","subChapters":[]}]},{"id":"480b9bd8-2745-538e-8416-9834b8d2d854","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field 1107150c-6c2c-4048-843a-f6f651a658bb --><h3>How should I monitor a person taking apixaban?</h3><!-- end field 1107150c-6c2c-4048-843a-f6f651a658bb -->","summary":null,"htmlStringContent":"<!-- begin item 0c83630a-d425-4236-aac9-7cfec2659c4b --><!-- begin field 58244267-e670-43ed-9b0c-8a2a0c984449 --><p><strong>There is no need to monitor the international normalized ratio (INR) in people taking apixaban; however, regular follow up and monitoring is recommended.</strong></p><ul><li><strong>At the start of treatment, </strong>baseline clotting screen, renal and liver function tests, and a full blood count should be performed.</li><li><strong>Once treatment has started, </strong>review the person on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. Follow-up intervals may be longer (up to every 6 months) or shorter (for example every month) depending on patient factors, such as renal function, age, and comorbidities.</li><li><strong>During a review:</strong><ul><li>Assess adherence to treatment.</li><li>Look for signs of bleeding or anaemia. </li><li>Ask about other <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#adverse-effects\">adverse effects</a> of apixaban.</li><li>Assess for features of thromboembolic events, such as symptoms of stroke, or breathlessness (which may suggest a pulmonary embolism). See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a> and <a class=\"topic-reference external-reference\" href=\"/topics/pulmonary-embolism/\">Pulmonary embolism</a> for more information.</li><li>Ask about the use of other medications, including over-the-counter (OTC) products, to identify possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#drug-interactions\">drug interactions</a> with apixaban.</li><li>Assess and minimize modifiable risk factors for bleeding, such as uncontrolled hypertension, medication predisposing for bleeding (such as aspirin), and excessive alcohol intake.</li><li>Give appropriate information and advice on apixaban treatment. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#advice-to-patients\">Advice for patients</a> for more information.</li></ul></li><li><strong>Repeat the <strong>full blood count and the </strong>renal and liver function tests yearly for most people.</strong><ul><li>If the person is frail or older than 75 years, repeat the blood tests every 6 months.</li><li>If the person has a creatinine clearance (CrCl) less than 60 mL/minute, the frequency of monitoring (in months) can be guided by the CrCl divided by 10. For example, every 3 months if CrCl is 30 mL/minute.</li><li>If the person has an intercurrent illness that may impact renal or hepatic function, repeat renal and liver function tests as needed.</li></ul></li><li><strong>Manage any problems identified during a review or from blood test results. </strong><ul><li>If renal function has declined, review treatment — apixaban may need to be stopped or a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#recommended-dose-treatment-duration\">lower dose</a> may be required. </li><li>If there is an unexplained fall in haemoglobin and/or haematocrit, occult bleeding may be present (apixaban can cause bleeding from any site) — stop treatment with apixaban and seek specialist advice. </li></ul></li><li><strong>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#monitoring-during-covid-19-pandemic\">Monitoring during Covid-19 pandemic</a> for more monitoring advice.</strong></li></ul><!-- end field 58244267-e670-43ed-9b0c-8a2a0c984449 --><!-- end item 0c83630a-d425-4236-aac9-7cfec2659c4b -->","subChapters":[{"id":"35d590b5-d150-5f7c-a65c-0c978e11997e","slug":"basis-for-recommendation-807","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3fc4aa87-c63d-4609-ae60-a6c6b5f3633e --><h4>Basis for recommendation</h4><!-- end field 3fc4aa87-c63d-4609-ae60-a6c6b5f3633e -->","summary":null,"htmlStringContent":"<!-- begin item 8073fe8c-9089-4ece-8541-319262410517 --><!-- begin field a2218dc6-684c-4b08-88cb-fa3e09c07933 --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>], the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>], the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update<em> Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</p><h5>Regular monitoring of apixaban treatment</h5><ul><li>No routine anticoagulant monitoring is required during treatment with apixaban — international normalized ratio (INR) tests give misleading results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>]. However, regular follow up and monitoring is recommended. </li><li>The European Heart Rhythm Association (EHRA) states that treatment with DOACs requires vigilance due to potentially severe complications, especially as the target patient population tends to be frail and of older age. According to the EHRA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>]:<br><ul><li>DOACs have an improved efficacy/safety ratio, a predictable anticoagulant effect without the need for routine coagulation monitoring, and fewer drug interactions than warfarin. However, treatment should be reviewed on a regular basis, preferably after 1 month initially and at least every 3 months thereafter. As clinical experience with these medications grows, follow-up intervals may become longer, based on individual (patient-specific) or local (centre-specific) factors. (The EHRA guideline gives a recommended follow-up interval of 1–6 months.)</li><li>The absence of a need for routine plasma level monitoring means that people taking DOACs are likely to be less frequently seen for follow-up appointments than people on warfarin treatment. Regular follow-up assessment is useful, especially for people with comorbidities (such as renal failure, older age, multiple comorbidities, or frailty).</li></ul></li></ul><h5>Renal function tests</h5><ul><li>Regular renal function tests are required as approximately 27% of apixaban is excreted renally. Exposure to apixaban is substantially increased in people with renal insufficiency, leading to an increased risk of bleeding. The EHRA advises that renal function should be monitored every 6 months if the person is frail or aged over 75 years, or more frequently if creatinine clearance (CrCl) is less than 60 mL/minute [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</li></ul><h5>Bleeding risk</h5><ul><li>The MHRA reminds healthcare professionals to remain vigilant for signs and symptoms of bleeding complications during treatment with apixaban after ongoing reports of serious, potentially fatal bleeds associated with the use of DOACs. Healthcare professionals are advised to use apixaban with caution in people with increased bleeding risk and to ensure that those with renal impairment are dosed appropriately and their renal function monitored during treatment. People should be counselled on the signs and symptoms of bleeding and encouraged to read the patient information leaflet [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020a</a>].</li><li>The SPCs and the BNF state that, as with other anticoagulants, people taking apixaban should be carefully monitored for signs of bleeding, and treatment should be discontinued if bleeding occurs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Joint Formulary Committee, 2020</a>].</li></ul><!-- end field a2218dc6-684c-4b08-88cb-fa3e09c07933 --><!-- end item 8073fe8c-9089-4ece-8541-319262410517 -->","subChapters":[]}]},{"id":"aeef5c1d-596a-58c7-859a-4fc141c09b32","slug":"monitoring-during-covid-19-pandemic","fullItemName":"Monitoring during Covid-19 pandemic","depth":3,"htmlHeader":"<!-- begin field ca2ade99-ccc3-44fa-b787-acb401762b5d --><h3>How should I monitor a person taking apixaban during the COVID-19 pandemic?</h3><!-- end field ca2ade99-ccc3-44fa-b787-acb401762b5d -->","summary":null,"htmlStringContent":"<!-- begin item e0d71699-f417-445a-a86a-a1c8e06e9aca --><!-- begin field c6e9db87-d191-4ddc-bcbb-acb401762b5d --><ul><li><strong>When monitoring a person taking apixaban during the COVID-19 pandemic, remember that:</strong><br><ul><li>Direct-acting oral anticoagulants (DOACs), such as apixaban, may <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#drug-interactions\">interact</a> with other medicines, including antibacterials and antivirals. Follow the advice in the manufacturer's Summary of Product Characteristics (SPC), available on the <a href=\"http://www.medicines.org.uk/emc\" data-hyperlink-id=\"bf6bda62-14be-48b6-a3bd-a98d000d45b6\">electronic Medicines Compendium</a> (eMC) website, to minimize the risk of potential interactions.</li><li>If switching from warfarin to apixaban, stop warfarin before starting apixaban, to reduce the risk of over-anticoagulation and bleeding. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#switching-anticoagulants\">Switching anticoagulants</a> for more information.</li></ul></li></ul><!-- end field c6e9db87-d191-4ddc-bcbb-acb401762b5d --><!-- end item e0d71699-f417-445a-a86a-a1c8e06e9aca -->","subChapters":[{"id":"b3056714-c63f-5c45-9653-96dd322083db","slug":"basis-for-recommendation-706","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 11e03264-ecdb-41ba-8de1-acb401762b5d --><h4>Basis for recommendation</h4><!-- end field 11e03264-ecdb-41ba-8de1-acb401762b5d -->","summary":null,"htmlStringContent":"<!-- begin item 70633bba-c6d4-42ce-ac12-886e9adabf4d --><!-- begin field 652d86a8-2f30-45ca-b9e8-acb401762b5d --><p>This recommendation is based on the Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update <em>Warfarin and other anticoagulants: monitoring of patients during the COVID-19 pandemic</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">MHRA, 2020b</a>].</p><!-- end field 652d86a8-2f30-45ca-b9e8-acb401762b5d --><!-- end item 70633bba-c6d4-42ce-ac12-886e9adabf4d -->","subChapters":[]}]},{"id":"fac4e678-cd03-58a4-8e1e-af47e738c876","slug":"managing-dosing-errors","fullItemName":"Managing dosing errors","depth":3,"htmlHeader":"<!-- begin field 5bcba5fd-8333-4559-bf18-a81d9bbc0e27 --><h3>How should I manage dosing errors in a person taking apixaban?</h3><!-- end field 5bcba5fd-8333-4559-bf18-a81d9bbc0e27 -->","summary":null,"htmlStringContent":"<!-- begin item 41a0782d-8cf4-4210-8b14-94a3c1de09e0 --><!-- begin field ea3dd62d-f95b-4501-bb63-6bf368848293 --><ul><li><strong>If the person has missed a dose of apixaban, </strong>the forgotten dose may be taken until half of the dosing interval has passed.<ul><li>This means that the forgotten dose can be taken up until 6 hours after the scheduled intake. After this time point, the dose should be skipped and the next scheduled dose should be taken.</li><li style=\"box-sizing: inherit;\">The 6-hour interval may be extended in people with a high stroke risk and low bleeding risk.</li></ul></li><li><strong>If the person has taken a double dose of apixaban, </strong>they should omit the next planned dose (that is, after 12 hours) and resume treatment as normal 24 hours after the double dose intake.</li><li><strong>If the person is uncertain whether they have taken their dose,</strong> it is generally advisable to not take another dose, but to continue with the next scheduled dose (that is, after 12 hours).</li></ul><!-- end field ea3dd62d-f95b-4501-bb63-6bf368848293 --><!-- end item 41a0782d-8cf4-4210-8b14-94a3c1de09e0 -->","subChapters":[{"id":"1ecb47d4-8159-5b11-bc6a-6dfa63c33789","slug":"basis-for-recommendation-5df","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e3129e59-2693-4d6a-b1bf-92763e921424 --><h4>Basis for recommendation</h4><!-- end field e3129e59-2693-4d6a-b1bf-92763e921424 -->","summary":null,"htmlStringContent":"<!-- begin item 5dfa0b38-6dd2-452c-9da6-1b1bb86749ed --><!-- begin field f66c6f5c-84da-4968-8ea4-12fa32260fb3 --><p>These recommendations are based on <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><p> </p><!-- end field f66c6f5c-84da-4968-8ea4-12fa32260fb3 --><!-- end item 5dfa0b38-6dd2-452c-9da6-1b1bb86749ed -->","subChapters":[]}]},{"id":"e4b56994-40e6-5b29-bbf9-aae81c856a8e","slug":"advice-to-patients","fullItemName":"Advice to patients","depth":3,"htmlHeader":"<!-- begin field 0cd94c2b-a71c-49cd-92ae-e9e847c06925 --><h3>What advice should I give a person who is taking apixaban?</h3><!-- end field 0cd94c2b-a71c-49cd-92ae-e9e847c06925 -->","summary":null,"htmlStringContent":"<!-- begin item 1eb24b73-0fcb-4e52-ba51-6db99ef6fb4e --><!-- begin field 37d42538-4368-479e-9448-d924d9019a0f --><ul><li><strong>Advise the person taking apixaban:</strong><ul><li>That although (unlike warfarin) there is no need to have regular blood tests to monitor the international normalized ratio (INR), they will still require regular <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#monitoring\">monitoring</a>, blood tests, and review of their treatment.</li><li>On the importance of a regular dosing schedule.<ul><li>The anticoagulant effect of apixaban reduces 12–24 hours after the last dose is taken; therefore, it is important to take the medication as directed or the person is at increased risk of a thromboembolic event.</li><li>They should not miss doses (or take additional doses) without advice from a healthcare professional.</li></ul></li><li>That they should seek immediate medical advice:<ul><li>If spontaneous bleeding occurs and does not stop or recurs. This includes bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in the urine or stools, haemoptysis, subconjunctival haemorrhage, and vaginal bleeding in a postmenopausal woman.</li><li>If they get sudden severe back pain (which may indicate spontaneous retroperitoneal bleeding).</li><li>If they experience difficulty breathing, increased breathing rate, or chest pain (which could be symptoms of pulmonary embolism).</li></ul></li><li>That they should also seek medical advice:<ul><li>If there has been a <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#managing-dosing-errors\">dosing error</a> (such as a missed dose or if a double dose has been taken).</li><li>Before taking other medications, including over-the-counter drugs (such as nonsteroidal anti-inflammatory drugs) and herbal remedies, due to possible <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#drug-interactions\">drug interactions</a> with apixaban. </li><li>If they experience other <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#adverse-effects\">adverse effects</a> of apixaban.</li></ul></li><li>That they may have to stop apixaban treatment temporarily for certain <a class=\"topic-reference internal-reference\" href=\"/topics/anticoagulation-oral/management/apixaban/#surgery-dental-treatment\">surgical and dental treatments</a>.</li><li>To read the manufacturer's <a href=\"https://www.medicines.org.uk/emc/product/4756/pil#gref\" data-hyperlink-id=\"e7074f8e-b101-46d1-a5e2-acb300c26292\">patient information leaflet</a>, if they have not already.</li><li>To carry an Eliquis® Patient Alert Card at all times. These are contained in each UK tablet pack and can also be printed off from the electronic Medicines Compendium (eMC) website (<a href=\"https://www.medicines.org.uk/emc/rmm/112/Document\" data-hyperlink-id=\"1f9e4007-f6cc-47b5-88c4-acae013e9255\">www.medicines.org.uk</a>).</li></ul></li></ul><!-- end field 37d42538-4368-479e-9448-d924d9019a0f --><!-- end item 1eb24b73-0fcb-4e52-ba51-6db99ef6fb4e -->","subChapters":[{"id":"f5e59e36-a9e7-506e-b43d-2c728470dcdd","slug":"basis-for-recommendation-f49","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 318f3c6c-c4cc-472b-8ce6-a8962c73d530 --><h4>Basis for recommendation</h4><!-- end field 318f3c6c-c4cc-472b-8ce6-a8962c73d530 -->","summary":null,"htmlStringContent":"<!-- begin item f496e110-2ba1-4d5e-aad7-e4baff7cdab3 --><!-- begin field 7b73113f-38d7-4ff1-aba0-87c7e3321b33 --><p>These recommendations are based on the manufacturer’s Summaries of Product Characteristics (SPCs) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">ABPI, 2020c</a>] and <em>The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/anticoagulation-oral/references/\">Steffel, 2018</a>].</p><!-- end field 7b73113f-38d7-4ff1-aba0-87c7e3321b33 --><!-- end item f496e110-2ba1-4d5e-aad7-e4baff7cdab3 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}